Samsara Vision

Company Overview

Snapshot

Founded in June 1994, Samsara Vision operates with 11–50 employees. The company has raised $90.5M across 6 funding rounds from 11 investors. In March 2021, Samsara Vision announced a European partnership with Medevise Consulting, signaling an expansion of its market reach.

Business overview

Samsara Vision develops implantable ophthalmic devices and technologies designed to enhance vision and quality of life for individuals suffering from end-stage age-related macular degeneration. Its core product, the Implantable Miniature Telescope, is central to the CentraSight treatment program, which guides patients through diagnosis, surgical evaluation, and postoperative care. This technology utilizes wide-angle micro-optics that, in conjunction with the cornea, create a telephoto system to magnify objects. The device is surgically placed within the eye, allowing for natural eye movements in various environments. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In March 2021, Samsara Vision announced a strategic European partnership with Medevise Consulting. This collaboration is a significant step for the company, indicating a focused effort to expand its market presence and distribution channels for its ophthalmic devices in the European region. For investors, this signals a proactive approach to market penetration and commercialization beyond its existing FDA approval and Israeli Ministry of Health clearances, potentially opening new revenue streams and increasing patient access to its vision-improving technologies.

Company Intelligence Q&A

What is Samsara Vision's primary focus?

Samsara Vision specializes in developing implantable ophthalmic devices and technologies aimed at improving vision and quality of life for individuals with end-stage age-related macular degeneration.

What is the company's flagship product?

The company's lead product is the Implantable Miniature Telescope, which is a key component of the CentraSight treatment program designed for patients with end-stage age-related macular degeneration.

Has Samsara Vision received regulatory approvals for its products?

Yes, the Implantable Miniature Telescope has received FDA approval in the United States, and Samsara Vision also holds a CE mark and approval from the Israel Ministry of Health for distribution and sale of the device.

What was a significant recent partnership for Samsara Vision?

In March 2021, Samsara Vision announced a European partnership with Medevise Consulting, aiming to expand its market reach and distribution in Europe.

When did Samsara Vision appoint new board members?

In January 2021, Samsara Vision appointed three new members to its Board of Directors.